1. Introduction {#s0005}
===============

The Philadelphia chromosome-negative (Ph −) MPNs include clonal disorders of myeloid progenitor cells, such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The latter can be sub-categorized as either primary (PMF) or as transformed from PV or ET (post-PV/ET MF) ([@bb0385]). The incidence of classic Ph − MPNs in Europe is 1.8 cases per 100,000 person-years ([@bb0455]). In the US, between 2008 and 2010 (as assessed by a review of two large health plans), the prevalences of PV, ET, and MF were 44--57, 38--57, and 4--6 per 100,000, respectively ([@bb0270]). In general, the MPNs may be associated with an increased risk of morbidity and mortality and may lead to a significant decrement in quality of life (QOL). Generally, MF differs from PV and ET in that it typically carries a worse prognosis and high symptom burden related to elevated cytokine levels, cytopenias, splenomegaly, and extramedullary hematopoiesis, all of which can result in fatigue, early satiety, abdominal discomfort, inactivity, night sweats, pruritus, bone pain and weight loss ([@bb0115]). Transformation to acute myelogenous leukemia (AML) has been the most feared complication of MPNs, particularly of MF.

Prognosis of MPNs varies greatly based on subtype. ET is associated with a 10-year and 15-year survival of 89 and 80%, leukemic transformation rate of 0.7% and 2.1%, and rate of progression to MF of 0.8% and 9.3%, respectively ([@bb0050]). Among patients with PV, median survival has been shown to be 14.1 years, which is worse than that of the age- and sex-matched control population of the US ([@bb0400]). Evolution to MDS and leukemia was the main cause of death in a phase 3 study comparing the use of hydroxyurea (HU) to pibobroman among treatment-naïve PV patients under the age of 65 years ([@bb0205]) In a large European epidemiological study of PV, 41% of deaths (1.5 deaths per 100 persons per year) were attributable to cardiovascular events ([@bb0245]). The median survival for patients with MF was shown to be 6.5 years, between years 1996 and 2007, in a European population ([@bb0075]).

A better understanding of the molecular pathogenesis of Ph − MPNs has been greatly facilitated by the 2005 discovery of the point mutation *JAK*2 V617F, which is present in almost 95% of PV cases and 50--60% of ET and PMF cases ([@bb0225], [@bb0340]). The mutation leads to constitutive activation of Janus kinase 2 (JAK2), a member of the Janus family of kinases, normally phosphorylated/activated by various cytokine receptors to drive signal transducer and activator of transcription (STAT) pathways in hematopoiesis ([Fig. 1](#f0005){ref-type="fig"}). The thrombopoietin receptor mutation *MPL* W515L, identified shortly after the discovery of *JAK*2 V617F, is another driver mutation that leads to activation of the JAK--STAT pathway and is present in a minority *JAK*2 V617F-negative cases of MF and ET ([@bb0315]). In 2013, mutations of *CALR*, the gene that encodes the endoplasmic reticulum chaperone calreticulin, were identified among 67--88% of patients with *JAK*2/*MPL* negative ET and MF ([@bb0210], [@bb0290]). The presence of these mutations may have prognostic implications for patients. For example, MF patients with *CALR* mutations have an improved overall survival as compared to patients with *JAK*2 mutations ([@bb0210], [@bb0290]), and ET patients with *CALR* mutations have a decreased incidence of thrombosis ([@bb0345]). The absence of mutations of *JAK*2, *CALR*, and *MPL* ("triple negative" PMF) appears to ultimately promote leukemic transformation, as compared with *CALR*-mutated or *JAK*2-mutated patients ([@bb0350]). These findings suggest that mutational status may be able to serve as a prognosticator independently from established prognostic models that are based on clinical features. Since the discovery of *JAK*2 V617F, there has been the identification of numerous other somatic mutations in MPNs (e.g., *JAK*2 exon 12, *IKZF*1, *DNMT*3*A*, *TP*53, *TET*2, *SRSF*2, *SF*3*B*1, *ASXL*1, *IDH*1/2, and *EZH*2). Many of these genes play roles in epigenetic processes, leading to activation or suppression of gene expression, suggesting a rationale for epigenetic therapies. Among MF patients, mutations in *ASXL*1, *SRSF*2, *IDH*, or *EZH*2 have been associated with a poor survival or an increased risk for leukemic transformation ([@bb0415]). Many of the other mutations seen in MPNs involve mRNA splicing and genes controlling cellular metabolism, and some may facilitate clonal selection and promote dominance of *JAK*2 V617F subclones ([@bb0285], [@bb0410]). The role of systematic mutational profiling to predict for benefit to therapy is the subject of current investigations, which will likely be challenging endeavors given the clonal complexity of MPNs ([@bb0240]).

2. Current Treatment of Classic Ph − MPNs {#s0010}
=========================================

Treatment decisions are generally based on MPN subtype, risk category, age, and disease manifestations. For PV and ET, thrombosis risk category often guides the decision to use cytoreductive and anti-platelet therapies (and phlebotomy for PV). Historically, treatment of MF has been guided by the patient\'s symptom profile and burden of disease, and has involved managing cytopenias (androgens, erythropoiesis stimulating agents, immunomodulatory agents) and splenomegaly (HU, busulfan, cladribine, splenectomy, splenic radiation, and immunomodulatory agents) and providing measures to prevent infections, control symptoms, and improve QOL (e.g., corticosteroids and stimulants) ([@bb0140], [@bb0390]). Treatment has also been based in part on the risk category (as an aid for selecting transplant candidates), assessed by the International Prognostic Scoring System (IPSS) or Dynamic IPSS/plus. Allogeneic hematopoietic stem cell transplant, typically reserved for fit patients with intermediate-2 or high-risk disease, is the only curative treatment option and may resolve bone marrow fibrosis, lead to molecular remission, restore normal hematopoiesis, and lead to cure in 40--70% of patients ([@bb0230], [@bb0045]). However, its association with significant morbidity and mortality limits its utility.

The oral selective JAK1/2 inhibitor ruxolitinib was assessed in a phase 1/2 study of 153 MF patients requiring therapy, identifying 25 mg orally twice daily or 100 mg once daily as the maximum tolerated doses, along with evidence of dose-dependent suppression of phosphorylated STAT3 ([@bb0435]). In the phase 2 portion, based on responses (at least 50% reduction of splenomegaly), toxicity, and need for dose reductions, 15 mg twice-daily was established as the optimal starting dose, and most patients experienced rapid improvement in debilitating MF-related symptoms. Ruxolitinib was FDA- and EMA-approved for the treatment of MF in 2011 and 2012, respectively, based on the results of two phase 3 studies in which ruxolitinib was compared to either placebo (COMFORT-1) or to best available therapy (COMFORT-2) ([@bb0440], [@bb0160]). Among the ruxolitinib-treated patients, a 35% or higher reduction in spleen size was achieved and maintained in 41.9% (versus 0.7% of placebo-treated patients) at week 24 in COMFORT-1 and in 32% and 28% (versus 0% of patients who received best available therapy) at weeks 24 and 48, respectively, in COMFORT-2. Moreover, in COMFORT-1, 45.9% of ruxolitinib-treated patients (versus 5.3%) achieved an improvement of at least 50% in the total symptom score ([@bb0440]). In COMFORT-2, pre-specified exploratory analyses showed that ruxolitinib-treated patients experienced improvements in quality of life, role functioning, and physical condition and reductions in MF-associated symptoms as compared to the patients who received best available therapy ([@bb0160]). The efficacy of ruxolitinib appeared to be dose-dependent and was not influenced by the presence or absence of the *JAK*2 V617F mutation, as patients with mutant and wild-type *JAK*2 responded similarly. Extended follow-up of these two studies demonstrated a survival advantage with the use of ruxolitinib among intermediate- and high-risk MF patients, while reduction in spleen size seemed to correlate with longer survival ([@bb0080], [@bb0420]). In the UK open-label, phase 2 ROBUST trial, involving 48 MF patients, 50% of all patients and 57% of intermediate-1 risk patients achieved the primary composite endpoint of treatment success, which was defined as ≥ 50% reduction in palpable spleen length and/or a ≥ 50% decrease in the Myelofibrosis Symptom Assessment Form Total Symptom Score at 48 weeks ([@bb0265]). An exploratory analysis of COMFORT-1 showed a reduction in MF-related hepatomegaly among the ruxolitinib-treated patients, providing rationale for using ruxolitinib in MF patients who undergo splenectomy ([@bb0450]). There are also reports of resolution of marrow fibrosis, reduction in *JAK*2 mutant allele burden, and even achievement of complete molecular remission with its long-term use ([@bb0495], [@bb0105]).

Ruxolitinib\'s FDA and EMA approvals were expanded in 2014 and 2015, respectively, to the treatment of PV patients who are intolerant of or resistant to HU, based on results from the RESPONSE trial, a phase 3 trial in which ruxolitinib was shown to be superior in regard to hematocrit control and spleen volume reduction as well as in suppressing disease-related symptoms ([@bb0425]). The most common adverse events, albeit usually low-grade, associated with ruxolitinib are anemia and thrombocytopenia, and other reported adverse events include headache, fatigue, diarrhea, nausea, and infections ([@bb0440], [@bb0160], [@bb0425]). Progressive multifocal leukoencephalopathy has been reported to occur in an elderly patient receiving the drug ([@bb0485]). The infectious complications of ruxolitinib may be at least partially explained by its impairment of dendritic cell development and function, including impairment of the dendritic cell\'s activation, migration, and ability to induce T-cell responses ([@bb0170]). These observations have prompted some investigators to recommend an infectious risk assessment and prophylaxis strategy ([@bb0165]). Three-year follow-up of the COMFORT studies showed that the rates of many of the adverse events generally decreased with longer exposure to ruxolitinib treatment, with the highest rates occurring within the first 6 months ([@bb0080]). It is also important to keep in mind that sudden withdrawal of ruxolitinib has been associated with a shock-like syndrome from the reemergence of suppressed inflammatory cytokines ([@bb0380]). However, such a severe withdrawal syndrome was not reported in the COMFORT and RESPONSE studies, but return of baseline MF-related symptoms typically occurs within approximately a week upon discontinuation of ruxolitinib ([@bb0440], [@bb0160], [@bb0425]).

In assessing ruxolitinib\'s position in the grand scheme of MPN treatment, two critical appraisals of the data from both the COMFORT trials suggested that the evidence to support ruxolitinib for the treatment of MF was limited, for various reasons, including trial design bias, limited sample size, comparator choice, and outcome indirectness ([@bb0055], [@bb0250]). Alternatively, an argument could be made that the data to support ruxolitinib\'s role in the treatment of MPNs are derived from randomized controlled trials with a relatively large sample size for an orphan disease, particularly one in which there is a paucity of other effective therapies.

To further define ruxolitinib\'s role, cost effectiveness studies have been conducted. The National Institute for Health and Care Excellence (NICE) obtained clinical and cost-effectiveness data from the drug manufacturer (derived from COMFORT-1 and COMFORT-2), and with this data, an independent study group concluded that there was significant uncertainty of the manufacturer\'s cost-effectiveness model due to its limitations. Despite conceding that ruxolitinib was clinically effective, NICE decided that ruxolitinib was not a cost effective use of National Health Service resources for treatment MF-related splenomegaly or disease symptoms in adults ([@bb0460]). A Finnish study assessed the cost effectiveness of ruxolitinib for the treatment of MF by creating a survival-based decision model based on data from COMFORT-2 and found that ruxolitinib produced 2.43 incremental quality-adjusted life years when compared to best available therapy, concluding that these gains came at reasonable costs, given the improvements in overall survival ([@bb0155]).

3. Other JAK Inhibitors {#s0015}
=======================

Beyond ruxolitinib, there are other JAK inhibitors under clinical investigation. The most advanced in development include momelotinib and pacritinib. As with ruxolitinib, momelotinib is a dual JAK1/2 inhibitor that has been shown to decrease splenomegaly and MPN-related symptoms in patients with intermediate or high-risk MF ([@bb0310]). Based on the International Working Group (IWG) criteria, 59% of evaluable patients in that phase I--II study experienced a response to anemia, and 70% of patients who had received red cell transfusions in the month prior to study entry achieved a minimum 12-week period of transfusion-independence. Grade 3/4 adverse reactions included thrombocytopenia in nearly third of the patients, while treatment-related grade 1 sensory peripheral neuropathy was seen in about a fifth of the patients. Currently ongoing are randomized studies of ruxolitinib versus momelotinib in MF patients (NCT01969838) and momelotinib versus best available therapy among MF patients who have already been treated with ruxolitinib (NCT02101268).

The other advanced phase JAK inhibitor, pacritinib, is a dual JAK2/FLT3 kinase inhibitor that has been shown to reduce splenomegaly and MF-related symptoms ([@bb0215]). A unique aspect of this inhibitor is the potential lack of significant anemia and thrombocytopenia noted with other JAK inhibitors. In a phase 2 study, in which 35 intermediate/high-risk MF patients were enrolled, 40% had hemoglobin \< 10 g/dL and 43% had platelets \< 100,000 × 10^9^/L at entry ([@bb0215]). The percentage change in hemoglobin measurements at each study visit relative to the baseline visit stayed within a median of 6%. Platelet count measurements decreased by a median of 12% at week 12 and 17.6% at week 24, but these levels remained stable through week 60. Grade 1/2 diarrhea and nausea were the most common adverse events (AEs). Two ongoing phases 3 trials are comparing pacritinib to best available therapy (NCT01773187 and NCT02055781).

4. Novel Treatment Strategies: Beyond JAK Inhibitor Monotherapy {#s0020}
===============================================================

Given the limitations of JAK inhibition as monotherapy, such as its inability to lead to CR in most patients and the prompt return of symptoms upon treatment discontinuation, there is a significant effort to develop new classes of therapeutic agents for MPNs, many of which are being studied as combination therapy with ruxolitinib. Although promising, there are a number of potential challenges with developing drug combinations for MPN treatment, taking into account the burgeoning number of putative drug targets and experimental agents in development, the inability to reliably predict synergist activity in the preclinical setting, relatively low disease incidence, and the increased complexity of assessing disease response and clinical benefit, as compared to that of many other diseases.

5. Interferon {#s0025}
=============

Interferon (IFN) alpha, a cytokine with antiviral, immunomodulatory, and growth inhibitory properties, has been of interest for the treatment of MPNs for decades ([@bb0195], [@bb0200]). Standard IFN alpha has been associated with hematologic response rates close to 80% for PV and ET, but its use is limited by toxicities, such as cytopenias, flu-like symptoms, and fatigue, leading to treatment discontinuation in up to 20% of patients. In a multicenter phase 2 study of pegylated (peg)-IFN alpha-2a involving 40 PV patients, there was a 95% complete hematologic response rate among the evaluable patients at 12 months and a 90% molecular response, as assessed by *JAK*2 V617F allele percentage, which declined from 45% at baseline to 3% after 36 months ([@bb0195], [@bb0200]). In another phase 2 study of peg-IFN, complete hematologic responses were achieved in 76% and 77% of patients with PV and ET, respectively, along with complete molecular response in 18% and 17% ([@bb0330]). However, twenty percent of the patients in this study discontinued the treatment because of drug-related toxicity. In addition to reductions in *JAK*2 V617F allele burden, *CALR* mutant molecular responses have also been noted among ET patients treated with peg-IFN ([@bb0430]). The next-generation, mono-pegylated IFN alpha-2b isoform, ropeginterferon alpha-2b, administered every 2 weeks, was assessed in a phase 1/2 study involving 51 PV patients, yielding an overall response rate of 90% and a complete response rate of 47% ([@bb0130]). The complete and partial molecular response rates were 47% and 43%, respectively. Overall, interferon treatment has major efficacy in the treatment of PV and ET, while its efficacy in MF is more limited and its role in MF management not well-defined ([@bb0180]).

6. Epigenetic Therapies {#s0030}
=======================

As mentioned, a number of recurrent somatic mutations observed in MPN are involved with epigenetic processes and include the following: *TET*2, involved with methylcytosine residue hydroxylation ([@bb0110]); *DNMT*3*A*, a cytosine methyltransferase ([@bb0010]); *IDH*1/2, oxidoreductases leading to 2-hydroxyglutarate production that inhibits alpha-ketoglutarate-dependent enzymes such as TET2 ([@bb0395]); *ASXL*1, involved with HOX gene regulation via Polycomb repressive complex 2 (PRC2)-mediated histone methylation ([@bb0015]); and *EZH*2, a histone methyltransferase component of PRC2 ([@bb0005]). Of note, JAK2 functions as an epigenetic modifier by affecting histone posttranslational modifications. Genome-wide methylation studies have revealed hyper- and hypomethylation in promoter regions and in non-CpG island loci among MPN samples, as compared with healthy controls, with differences also noted between PMF and PV/ET samples ([@bb0295]). Particular methylomic signatures were associated with the presence of *ASXL*1 and *TET*2 mutations. Also supporting the role of epigenetic aberration in the pathogenesis of MPNs, histone deacetylase (HDAC) activity has been observed to be elevated in PMF patients as compared with other MPN patients and healthy volunteers, with HDAC levels correlating to degree of splenomegaly ([@bb0465]). Global gene expression profiling of blood from patients with MPNs has revealed abnormalities in the expression of various HDAC genes ([@bb0370]).

6.1. HDAC Inhibitors {#s0035}
--------------------

Given the abundance of evidence that epigenetic deregulation is involved in MPN pathogenesis, targeting epigenetic processes is of great therapeutic interest. As a class, the HDAC inhibitors (HDACis), four of which are currently FDA-approved for use in T-cell lymphomas or multiple myeloma, along with the DNA methyltransferase inhibitors, have led the way in epigenetic therapy for the treatment of malignancies. Histone modification patterns, regulated by histone acetyl transferases and HDACs, guide the recruitment of various transcription factors to maintain and perform normal cellular functions ([@bb0255]). Dysregulation of this epigenetic process can result in suppression of transcription of tumor suppressor and cell differentiation genes, contributing to MPN pathogenesis ([Fig. 2](#f0010){ref-type="fig"}). There have been numerous preclinical and clinical studies in recent years that have provided proof of principle that HDAC inhibition confers some degree of anti-neoplastic activity among MPNs. The HDAC inhibitor givinostat was found to induce apoptosis in *JAK*2 V617F MPN cells to a greater degree than in JAK2 wild type cell lines, and global gene expression analysis revealed that it modulated expression of multiple genes that are implicated in cell cycle regulation and hematopoiesis ([@bb0020]). Among MPN cell lines and CD34 + cells from MPN patients, givinostat inhibited proliferation and erythroid differentiation and increased histone H3 acetylation at the promoter of NFE2, a gene involved with hematopoiesis. Furthermore, it independently inhibited JAK--STAT signaling. In combination with hydroxyurea, it synergistically potentiated the induction of pro-apoptotic effects in the JAK2 V617F MPN cell lines ([@bb0025]).

Two other HDAC inhibitors, trichostatin A and vorinostat, were able to restore expression of miR-375, which is a negative regulator of JAK--STAT signaling ([@bb0505]). Forced expression of miR-375 has been previously shown to inhibit constitutive and inducible JAK2/STAT signaling, suppresses cell proliferation, and decreases colony formation in hematopoietic progenitors from MPN patients. In a phase 2 study in which givinostat was administered to *JAK*2 V617F-mutated PV, ET, and MF patients (n = 29) starting at 50 mg orally twice daily and given for a median of 20 weeks, 3 major responses were observed among 16 MF patients ([@bb0335]). Among 13 PV/ET patients, 1 complete and 6 partial responses were noted, while pruritus and splenomegaly reduction was observed in 75% of PV/ET and 38% of MF patients. Dose reduction and/or temporary interruption was required in 10 and 15 of the patients, respectively. In another phase 2 study, using two different doses of givinostat in combination with hydroxycarbamide (HC) among PV patients unresponsive to the maximum tolerated dose (MTD) of HC, complete and partial responses were observed in 55% and 50% of patients receiving 50 and 100 mg of givinostat, respectively ([@bb0125]). Pruritus reduction was observed in most of the patients. Among 22 intermediate/high-risk MF patients treated with the HDAC1 inhibitor pracinostat in a phase 2 study, 36% experienced clinical benefit, but 91%, 13%, and 21% experienced fatigue, grade 3/4 neutropenia, and grade 3/4 thrombocytopenia, respectively. Almost all of the patients discontinued therapy, primarily due to lack of efficacy ([@bb0325]). A phase 2 study involving 63 ET/PV patients demonstrated a 35% response rate along with pruritus and splenomegaly reduction and a reduction in *JAK*2 V617F allelic reduction, but more than half of the patients discontinued treatment mainly due to significant toxicity, including diarrhea, fatigue, and renal impairment ([@bb0030]). Similarly, in a phase 2 study of pan-deacetylase inhibitor panobinostat in MF patients, some evidence of efficacy was noted, but toxicity led to significant treatment discontinuation ([@bb0100]). Given the seemingly low therapeutic index of HDACis for the treatment of MPN, studying HDACis at lower doses, in combination with other agents may be warranted. As supported by preclinical studies ([@bb0470], [@bb0120]), two clinical trials of panobinostat in combination with ruxolitinib for the treatment of MF are ongoing (NCT01693601 and NCT01433445).

6.2. Hypomethylating Agents {#s0040}
---------------------------

There is a potential role for the other major class of epigenetic modifying agents, DNA methyltransferase inhibitors, also known as hypomethylating agents (HMA), in treating MPNs, as evidenced by results of preclinical and clinical studies. Treatment of PMF CD34 + and normal CD34 + cells with the HMA decitabine, followed by HDAC inhibitor suberoylanilide hydroxamic acid or trichostatin A resulted in apoptosis in the former but not in the latter ([@bb0475]). With transplantation of HMA/HDAC inhibitor-treated *JAK*2 V617F + PMF CD34 + cells into non-obese diabetic/severe combined immunodeficient mice, the percentage of *JAK*2 V617F + cells progressively declined from 2 to 6 months, in comparison with that of mice transplanted with cells treated with cytokines ([@bb0475]). A retrospective study of 45 patients with MPN transformed to AML, MPN in accelerated phase, or high-risk PMF treated with decitabine revealed response rates that ranged from 29% to 82%, response durations of 6.5 to 9 months, and an improvement in overall survival among responders as compared with non-responders ([@bb0035]). There are clinical trials evaluating the activity of decitabine for patients with MF and high-risk MPNs, as a single agent and in combination with JAK inhibitors (NCT00095784, NCT02564536, and NCT02076191). Limited clinical activity of 5-azacitidine was observed in a trial involving 34 MF patients, with a 24% response rate after a median of 5 months of treatment ([@bb0320]). An assay for global DNA methylation showed a decrease from 53% methylation pre-therapy to 44% on day 14 and a return to 50% at the end of the first 28-day cycle. Trials of azacitidine in combination with ruxolitinib and with a hedgehog inhibitor are underway (NCT01787487 and NCT02129101).

6.3. Bromodomain Inhibition {#s0045}
---------------------------

Bromodomains are a highly conserved protein motif able to recognize acetylated lysine residues of histone and nonhistone proteins and serve as epigenetic readers and regulators that participate in DNA replication, chromatin remodeling, DNA damage, and transcriptional regulation ([Fig. 2](#f0010){ref-type="fig"}) ([@bb0095]). They exist in a tandem structure at the N-terminal of more than 40 different human proteins and belong to one of nine major families, one of which is the bromodomain and extraterminal (BET) family, comprising bromodomain-containing proteins 2, 3, 4, and T. Bromodomain 4, for example, is involved with transcriptional initiation and elongation by associating with mediator complex and with positive transcription elongation factor b, respectively ([@bb0095]). Abnormalities involving BET proteins may contribute to the pathogenesis of a number of malignancies, including multiple myeloma, Burkitt\'s lymphoma, AML with MLL translocations, NUT midline carcinomas, and MPNs ([@bb0095], [@bb0500]). These observations have prompted ongoing efforts to develop BET inhibitors, which inhibit the ability of BET proteins to interact with acetylated lysine residues on histones. The BET inhibitor I-BET151 was shown to inhibit growth and, along with a JAK2 inhibitor, induce apoptosis among JAK2 inhibitor-resistant human erythroleukemic (HEL) cell lines via downregulation of LMO2, an oncogenic regulator that is dependent upon JAK2 kinase activity in HEL cells ([@bb0500]). I-BET151 inhibited erythroid colony formation among JAK2 mutant but not wild-type JAK2 associated erythroid colonies taken from PV patients. Also of particular interest is BET\'s role in regulating MYC and that inhibition of BET bromodomain--promoter interactions results in a reduction of MYC transcript and protein levels resulting in G1 arrest and extensive apoptosis in various leukemia and lymphoma cell lines ([@bb0085]). Currently, two phase 1 trials assessing BET inhibitors are enrolling patients with myeloproliferative neoplasms (NCT02158858, NCT02431260).

7. PI3K/Akt/mTOR Pathway Inhibition {#s0050}
===================================

A number of agents that target various nodes of the phosphoinositide-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, including PI3K and mTOR inhibitors, are currently in development for the treatment of MPNs. This pathway is a crucial regulator of cell growth, survival, and metabolism conditions ([@bb0360], [@bb0280]). It mediates ribosomal translation of mRNA, via downstream effectors 4EBP1 and S6K, into proteins required for cell growth, cycle progression, and metabolism. The overactivation of this pathway, which can be result from constitutive activity of upstream JAK2 ([Fig. 1](#f0005){ref-type="fig"}), has been observed in MPNs, and its various roles in the pathogenesis of MPNs has been reviewed in detail elsewhere ([@bb0060], [@bb0305], [@bb0260]). In brief, the PI3K/Akt/mTOR pathway may mediate disease progression as well as cellular drug resistance. The rapalog mTOR inhibitor everolimus, currently approved for the treatment of various advanced solid tumors, was shown to have clinical activity in MF in a phase 1/2 clinical trial ([@bb0145]). Of 30 evaluable high/intermediate-risk MF patients who had received prior therapy, splenomegaly reduction of \> 50% and \> 30% occurred in 20% and 44%, respectively, and 69% and 80% experienced complete resolution of constitutional symptoms, respectively. The responses were not associated with a reduced *JAK*2 V617F allele burden or with cytokine levels. Grade 1/2 stomatitis was the most common toxicity, occurring in the majority of subjects. Of great clinical interest, based on the results of multiple preclinical studies, is the combination of PI3K/Akt/mTOR inhibitors with JAK inhibitors ([@bb0090], [@bb0065], [@bb0375]). In a cellular screening assay, synergistic anti-proliferative activity was observed in JAK2-mutated MPN mouse Ba/F3 cells when subjected to combinations of various pan-class I PI3K inhibitors and JAK inhibitors ([@bb0090]). Moreover, in murine MPN models, the PI3K/JAK inhibitor doublets synergistically improved survival and delayed onset of splenomegaly ([@bb0090]). The use of BEZ235, a dual PI3K/mTOR inhibitor, alone or in combination with ruxolitinib, in in vitro and in vivo preclinical models of *JAK*2 V617F-mutated MPN, also led to synergism ([@bb0065]). Other classes of agents of interest include the catalytic mTORC1/2 inhibitors and AKT inhibitors. Currently, a number of clinical trials involving the use of PI3K/AKT/mTOR inhibitors alone or in combination are in progress (NCT01730248 and NCT02493530).

8. Telomerase Inhibition {#s0055}
========================

Telomeres, which are nucleoproteins located at the ends of chromosomes, maintain genome stability by protecting the ends of chromosomes from degradation ([@bb0300]). Many neoplastic cells are able to obviate this replicative senescence by activating telomerase, a reverse transcriptase that maintains telomere length by adding nucleotides to the telomere during cell division. Telomerase inhibition has been demonstrated to induce this process among neoplastic cells ([@bb0300]). Imetelstat, an intravenously administered, 13-mer lipid-conjugated antisense oligonucleotide that targets the RNA template component of telomerase, conferred an 89% overall response rate in a phase 2 study of 18 ET patients for whom first-line therapy had failed ([@bb0040]). Ten of the patients received therapy for a median of 17 months, and among the 8 patients with *JAK*2 V617F mutations, molecular responses were noted in 7. In a pilot study involving 33 MF patients, half of whom had received prior JAK inhibitor therapy, 21% attained a complete (n = 4) or partial remission (n = 7; CR, PR) of a median duration of 18 and 10 months, respectively ([@bb0405]). Response rates were higher among those with wild-type *ASXL*1, as compared to mutated *ASXL*1 (32% versus 0%, P = 0.07), and among those with a mutation in *SF*3*B*1 or *U*2*AF*1, as compared with their wild-type counterparts (38% versus 4%, P = 0.04). Among the CR patients, bone marrow fibrosis reversal and molecular responses were noted in 100% and 75%, respectively. Baseline telomere length was not predictive of response. In both of these studies, grade 3/4 cytopenias occurred in approximately 10--30% of patients, and many of the patients had low-grade liver function test abnormalities. In addition to antisense oligonucleotide strategies, the use of telomerase-targeting small molecules and immunotherapy represent potential strategies ([@bb0275]).

9. Hedgehog Pathway Inhibition {#s0060}
==============================

Hedgehog (Hh) is a highly conserved signaling pathway, components of which include cell surface receptor Patched-1 (PTCH1), transmembrane receptor Smoothened (SMO), and three glioma associated family transcription factors (GLI) ([@bb0190]). It is involved with multiple essential processes, including stem cell maintenance, cell cycle regulation, apoptosis, and cellular proliferation, and interacts with many other pro-survival pathways such as RAS--ERK--MAPK and PI3K/Akt/mTOR. There is evidence of Hh pathway dysregulation in a number of malignancies including MPNs, in which a 20--100 fold increase in expression of Hh target genes has been noted in granulocytes isolated from MPN patients and among preclinical models of PMF ([@bb0070]). In a murine bone marrow transplant model of ET/MF, the use of the selective SMO inhibitor sonidegib (LDE-225) in combination with ruxolitinib significantly reduced blood counts, mutant allele burden, and bone marrow fibrosis as compared to that observed with ruxolitinib as monotherapy ([@bb0070]). Among 23 intermediate/high-risk MF patients treated with the combination of these same two agents in the phase 1b portion of a phase 1b/2 study, 65% achieved a ≥ 50% reduction in palpable spleen length from baseline ([@bb0150]). In a phase 1a study of SMO inhibitor PF-04449913 for patients with hematological malignancies (n = 32), five of the six MF patients attained stable disease, and the sixth stayed on study for over a year while achieving durable clinical improvement with a \> 50% reduction in extramedullary disease ([@bb0185]). For both of these studies, the results from the phase 2 portions are awaited (NCT01787552 and NCT02226172). In a phase 2 study, oral SMO inhibitor IPI-926 was administered to 14 MF patients, all of whom discontinued treatment by 7.5 months primarily due to lack of effectiveness ([@bb0365]). There was no significant reduction in symptoms and splenomegaly and insignificant reductions in *JAK*2 V617F allele burden and marrow fibrosis. AEs consisted mainly of low-grade gastrointestinal and hepatic toxicities. The lackluster results did not support the continuation of the development of this particular agent. Another SMO inhibitor, erismodegib, is being assessed in combination with azacitidine in a phase 1 study for various myeloid malignancies, including MPNs (NCT02129101).

10. PIM Kinase Inhibition {#s0065}
=========================

Proviral Integration of Moloney virus (PIM) is a family of pro-survival serine/threonine kinases, comprising PIM1, PIM2, and PIM3, involved with regulating the cell cycle, cellular metabolism, proliferation, survival, and cross-talking with Akt kinase ([@bb0480]). PIM1 expression is induced by JAK2/STAT5 signaling ([Fig. 2](#f0010){ref-type="fig"}), suggesting some involvement of PIM activity in MPN pathogenesis ([@bb0235]). PIM kinase inhibitors SGI-1776 and AZD1208 inhibited growth and viability of *JAK*2 V617F-dependent MPN model and MPN patient cells in a dose-dependent manner, and activity was enhanced when used in combination with ruxolitinib. Both of these PIM kinase inhibitors, as single agents, inhibited erythropoietin-independent erythroid colony formation of primary cells from MPN patients but not from normal controls. AZD1208 administered in combination with ruxolitinib synergistically inhibited colony formation of primary cells from MPN patients ([@bb0235]). In another set of studies, PIM inhibitor LGH447 in combination with ruxolitinib led to significant modulation of PIM1/2 and pSTAT3/5, respectively, among *JAK*2 V617F-mutated MPN cell lines, and both agents inhibited pERK and pS6 in one of the cell lines ([@bb0355]). This drug combination also resulted in a greater reduction of overall disease burden and spleen weight than either agent alone in a mouse MPN model. The observation of the suppression of MYC protein levels among MPN cell lines after treatment with various PIM kinase inhibitors provides further support of PIM\'s role in MPN pathogenesis ([@bb0175]). Using a pooled small hairpin RNA library screen among an MPN cell line, MYC was identified as a top therapeutic target in the setting of JAK2 inhibition. Considering that PIM kinases directly phosphorylate MYC, resulting in stabilization of MYC, various pan-PIM inhibitors were tested, in combination with JAK2 inhibitor SAR302503, against MPN cell lines, demonstrating synergistic MPN cell growth inhibition, apoptosis, and eradication of JAK2 inhibitor-resistant MPN clones. There is currently a phase 1/2 trial evaluating pan-PIM inhibitor INCB053914 among patients with MF (NCT02587598) and a phase 1 trial evaluating another pan-PIM inhibitor PIM447 (formerly LGH447), ruxolitinib, and a CDK 4/6 inhibitor in doublet and triplet combinations for patients with MF (NCT02370706).

11. Glutaminase Inhibition {#s0070}
==========================

Among *JAK*2 V617F-mutant cells in vitro, as compared with their wild-type counterparts, there has been the observation of increased oxygen consumption, increased extracellular acidification, increased glutamine metabolism, and upregulated glutaminase ([@bb0510]). Glutaminase expression was increased in *JAK*2 V617F-mutant peripheral blood CD34 + cells as compared to *JAK*2 wild-type progenitor cells from the same patients MPN patients, and its expression increased further with disease progression. The glutaminase inhibitor, BPTES, along with ruxolitinib, using various laboratory assays, led to an increased anti-proliferative effect among these *JAK*2 V617F-mutant cell lines and MPN patient peripheral blood CD34 + cells from MPN patients than that of ruxolitinib alone ([@bb0510]). These observations, along with the knowledge that neoplastic cells generally rely upon aerobic glycolysis more than normal cells do (i.e., Warburg effect), provide the rationale for the clinical investigation of the role of glutaminase inhibitor therapy, with or without JAK inhibition, among MPN patients requiring therapy.

12. Other Therapeutic Strategies {#s0075}
================================

There are multiple other classes of agents, some of which are in clinical development, with potential therapeutic benefit for MPN patients. These include agents that target heat shock protein-90, isocitrate dehydrogenase, and mitogen/extracellular signal-regulated kinase (MEK) ([@bb0490], [@bb0395], [@bb0220]). PRM-151, a recombinant human pentraxin-2 with anti-fibrosing properties, is currently being evaluated in a phase 2 clinical trial for patients with MF (NCT01981850). Aurora A kinase inhibitors, which have been shown to induce megakaryocytic polyploidization, induce growth arrest and apoptosis of a megakaryoblastic cell line, and decrease disease burden in a murine model, are also of great clinical interest ([@bb0445], [@bb0135]). A multicenter pilot study involving the Aurora A kinase inhibitor alisertib for the treatment of MF patients has recently been launched (NCT02530619).

13. Conclusion {#s0080}
==============

The need for optimal treatment options for many patients with MPN persists, despite the advent of ruxolitinib. In general, JAK inhibitor monotherapy has considerably improved patient well-being, ameliorating MPN symptoms and splenomegaly, but disease remission is not an expectation. Given the ability to relieve symptoms, JAK inhibitor therapy may become an essential cornerstone of combination therapy with other novel agents, which may address other aspects of disease pathogenesis.

14. Outstanding Questions {#s0085}
=========================

Efforts continue to identify relevant, targetable pathogenetic pathways in MPNs, with the goal of improving efficacy and decreasing off-target toxicity of therapy. Further therapeutic efforts may be facilitated by addressing the following questions or issues: a better understanding of the mechanisms of action of novel agents; accurate identification of predictive biomarkers of response to therapy; the optimal time to initiate a particular therapy for any given individual, given the clinical heterogeneity of MPNs and that many patients will fare well with currently established general treatment options, such as phlebotomy, aspirin, and use of cytoreductive agents; how clinical trials may be judiciously designed and conducted, given the relatively low incidence of MPNs along with the limitless potential drug combinations; with new, effective therapies, how allogeneic hematopoietic stem cell transplantation should be incorporated into the treatment paradigm.

15. Search Strategy and Selection Criteria {#s0090}
==========================================

Data for this Review were identified by searches of PubMed, the abstract libraries of the American Society of Hematology and the American Society of Clinical Oncology, and [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#ir0005}, using the search terms "myeloproliferative neoplasm" "novel" "targeted therapy" "pathobiology" and the names of the classes of agents discussed in the Review.
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![JAK-STAT signaling contributes to the pathogenesis of MPNs. Unregulated JAK-STAT signaling, leading to STAT-mediated hematopoiesis and activation of the PI3K/Akt/mTOR pathway, may result from a number of aberrations including point mutations JAK2 V617F, leading to constitutive activation of JAK2 kinase, and MPL W515L, an activating mutation of the thrombopoietin receptor. Number small molecule inhibitors of these pathways, including JAK, PI3K, and mTOR inhibitors, are in clinical development. Epo, erythropoietin; JAK, Janus kinase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide-3 kinase; STAT, signal transducer and activator of transcription; Tpo, thrombopoietin; -i, inhibitor.](gr1){#f0005}

![Examples of other aberrantly regulated molecular signaling pathways and targets in MPNs. HDAC-mediated deacetylation of the lysine residues of histone tails lead to chromatin condensation and transcriptional silencing of tumor suppressor genes ([@bb0465]). PIM kinase expression, induced by JAK-STAT signaling, is involved in a number of prosurvival functions, one of which is phosphorylation and stabilization of Myc. The BET family of BRD proteins includes BRD4, which has a pocket for acetylated lysine residues of the histone tail. BET, bromodomain and extraterminal family of bromodomain-containing proteins; BRD4, bromodomain-containing protein 4; HDAC, histone deacetylase; PIM; proviral integration of Moloney virus; STAT, signal transducer and activator of transcription, -i, inhibitor.](gr2){#f0010}
